RebrandingJul 31, 2026, 08:34 AM
Plus Therapeutics Rebrands to Cerenome, Changes Ticker to CNSY
AI Summary
Plus Therapeutics, Inc. announced its corporate rebrand to Cerenome, Inc., effective August 3, 2026. Concurrently, the company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol "CNSY." This strategic rebrand signifies the company's evolution from a therapeutics-focused organization into an integrated CNS oncology company, combining precision diagnostics, targeted therapeutics, and proprietary data within a single entity to improve outcomes for CNS cancer patients.
Key Highlights
- Company will rebrand from Plus Therapeutics, Inc. to Cerenome, Inc.
- Effective August 3, 2026, the company's common stock will trade under new ticker "CNSY" on Nasdaq.
- The rebrand reflects an evolution into an integrated CNS oncology company.
- Cerenome will integrate precision diagnostics (CNSide®), targeted therapeutics (REYOBIQ™), and proprietary data/AI.
- The strategy aims to improve CNS cancer detection, treatment, and understanding.
- The change does not affect shareholders' ownership interests; shares will automatically reflect the new name and ticker.
Price Impact
More from PSTV